Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab and Bortezomib in Relapsed or Refractory Low-Grade Non-Hodgkin Lymphoma
NCT01119794Phase 2Terminated
- Sponsor
- Brown University
- Start
- Jul 2010
- Primary completion
- Jul 2015
- Modality
- Monoclonal Antibodies, Modified Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ofatumumab and bortezomib in non-Hodgkin lymphoma (NHL), sponsored by Brown University. Primary endpoint: Overall Response Rate at 2 years. Started Jul 2010; status: terminated.
02
Drugs
ofatumumabbortezomib
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT01119794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01119794.